The Society of Thoracic Surgeons Intermacs 2020 Annual Report. [Review]

The Society of Thoracic Surgeons Intermacs 2020 Annual Report. [Review] - 2021

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

The STS-Intermacs 2020 Annual Report reviews outcomes on 25,551 patients undergoing primary isolated continuous flow left ventricular assist device (LVAD) implantation between 2010-2019. In 2019, 3,198 primary LVADs were implanted, which is the highest annual volume in Registry history. Compared with the previous era (2010-2014), patients implanted in the most recent era (2015-2019) were more likely to be African American (26.8% vs. 22.9%, P<.0001) and more likely to be bridged to durable LVAD with temporary mechanical support devices (36.8% vs 26.0%, P<.0001). In 2019, 50% of patients were INTERMACS 1-2 prior to durable LVAD and 73% were implanted as destination therapy. Maglev technology has become the predominant design, accounting for 77% of devices in 2019. The 1- and 2-year survival in the most recent era has improved compared to 2010-2014 (82.3% and 73.1% vs. 80.5% and 69.1%, respectively; P<.0001). Major bleeding and infection continue to be the leading adverse events. Incident stroke has declined in the current era to 12.7% at one-year. STS-Intermacs research publications are highlighted herein and the new quality initiatives are introduced. Copyright (c) 2021. Published by Elsevier Inc.


English

0003-4975

10.1016/j.athoracsur.2020.12.038 [doi] S0003-4975(21)00074-6 [pii]


*Heart Failure/su [Surgery]
*Heart-Assist Devices
*Registries
*Societies, Medical
*Surgeons
*Thoracic Surgery
Humans
United States


MedStar Heart & Vascular Institute


Journal Article

Powered by Koha